With a market capitalization (market cap) of $10.25B — a measure of how much the company is worth — Insulet Corp. is the 949th most valuable company in Healthcare as of August 18, 2026. Shares trade at $148.03, up +5.96% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Visit websiteAs of August 18, 2026, Insulet Corp. (PODD) is worth $10.25B — this is its market capitalization, the total value of all its outstanding shares.
Insulet Corp.’s market cap is $10.25B, which ranks it #949 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Insulet Corp. (PODD) shares trade at $148.03, up 5.96% on the day, as of August 18, 2026.
Insulet Corp. trades at a price-to-earnings (P/E) ratio of 42.2, based on its latest share price and annual earnings per share.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025